Fig. 3: VES PD responses in CCMM + VES and placebo recipients. | Nature Communications

Fig. 3: VES PD responses in CCMM + VES and placebo recipients.

From: Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Fig. 3

Serum levels were measured by single-molecule array assay for IFNα and multiplex cytokine assay for IP-10 (CXCL10), ITAC (CXCL11), and IL-1RA at baseline (BL), before and 24 h after the first VES/placebo dose (week 26), and before and 24 h after the 10th (last) VES/placebo dose (week 46). Colored-coded dots represent data collected from individual participants (red color was used to mark participants receiving CCMM + VES and blue for those receiving placebo). Median and IQR are shown with black dots and lines. Wilcoxon test was used to compare data at given timepoints between groups (unpaired) or data from two different timepoints within the same group longitudinally (paired; shown by brackets), reported using nominal P values. *P ≤ 0.0500, **P ≤ 0.0100, ***P ≤ 0.0010. CXCL C-X-C motif chemokine ligand.

Back to article page